Global policy and access to new hepatitis C therapies for people who inject drugs [PDF]
Aspinall, Esther +6 more
core +1 more source
Identification of Candidate Inhibitors to SARS-CoV-2's Enzymes and Potential Disruptors of Its Structural Proteins' Interactions. [PDF]
Mohammadian A +4 more
europepmc +1 more source
Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. [PDF]
Boonpheng B, Ungprasert P.
europepmc +1 more source
Consideration of ledipasvir/sofosbuvir as an alternative to glecaprevir/pibrentasvir based upon on-treatment FIB-4 changes and sustained virologic response at 12 weeks in hepatitis C genotype 1 and 2 infections: A propensity score-matched study. [PDF]
Park HJ +5 more
europepmc +1 more source
Efficacy and safety of sofosbuvir-based therapies for treating HCV in children: observations from a real-world setting. [PDF]
Pokorska-Śpiewak M +4 more
europepmc +1 more source
Sensitive RP-HPLC method with fluorimetric detection for concurrent quantification of emtricitabine, Daclatasvir and Ledipasvir in human urine. [PDF]
Youssef AA +3 more
europepmc +1 more source
Exploring stationary phase morphologies as pathways to greener and faster LC for analyzing sofosbuvir and ledipasvir. [PDF]
Ibrahim AE +4 more
europepmc +1 more source
An eco-friendly chemometrics assisted UV spectrophotometric method for simultaneous determination of sofosbuvir, simeprevir and ledipasvir in pharmaceuticals. [PDF]
Alshehri A +3 more
europepmc +1 more source
Generic <i>vs</i> brand forms of direct acting antivirals for hepatitis C virus treatment in Egyptian children. [PDF]
Mogahed E +4 more
europepmc +1 more source

